Listed by the USPTO as SHUPE, ELIZABETH A
Tech Center 1600 • Art Units: 1643 1644 1645
This examiner grants 66% of resolved cases
SHUPE, ELIZABETH A is assigned to tech center 1600 and art unit 1643. The record includes 76 resolved cases, an allowance rate of 65.8%, and a median of 1348 days to allowance. The 45.5% interview lift is a significant feature relative to the allowance rate as a percentage measure. The extended median timing indicates that a favorable allowance outcome may still require prolonged prosecution.
The leading companies are The Regents of the University of California, University of Virginia Patent Foundation, and Maddon Advisors LLC. The firms are COOLEY LLP, Knobbe, Martens, Olson & Bear, LLP, and Law Offices of Alan J. Morrison. The limited resolved-case total calls for measured use of the profile, but the company and firm names can help identify relevant experience in art unit 1643.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18464580 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 18249907 | MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING TUMOR ASSOCIATED MACROPHAGES (TAMS) | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17998641 | METHODS AND ANTIBODIES IN TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | Non-Final OA | The Regents of the University of California |
| 18547652 | CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALING MOLECULES FOR CONTROLLED AND SPECIFIC CAR T CELL ACTIVITY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18114057 | Dosing Regimens for Mitigation of Cytokine Release Syndrome | Non-Final OA | Regeneron Pharmaceuticals, Inc |
| 18668561 | ANTI-PMEPA-1 ANTIBODIES OR ANTIGEN BINDING FRAGMENTS THEREOF, COMPOSITIONS, AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 18031969 | COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS | Final Rejection | University of Virginia Patent Foundation |
| 17050231 | COMPOSITIONS AND METHODS FOR TREATING ABDOMINAL AORTIC ANEURYSM | Final Rejection | University of Virginia Patent Foundation |
| 18308899 | NOVEL CELLULAR RECEPTORS AND USES THEREOF | Non-Final OA | TRUSTEES OF BOSTON UNIVERSITY |
| 17263675 | METHOD FOR PRODUCING CD3-POSITIVE CELL | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18199154 | INDUCIBLE CELL DEATH SYSTEMS | Non-Final OA | Senti Biosciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy65.8% of resolved applications examined by Elizabeth A Shupe were allowed (76 resolved cases), compared with 41.5% across Art Unit 1643 over the last five years.
This examiner's interview lift is +45.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Elizabeth A Shupe took 1,348 days on average from filing to allowance.
Elizabeth A Shupe examines applications in Art Unit 1643 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
